1、Chen X, Wu J, Lu H, Huang O, Shen K#. Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. Cancer Sci,2012;103(2):262-8.
2、Chen X, Yuan Y, Gu Z, Shen K#. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat,2012;134(3):957-67.
3、沈坤炜, 李宏为. 乳腺癌诊治进展—多学科与个体化. 中国实用外科杂志,2011;31(10):891-893.
4、Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW#. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. Tumori,2010; 96(1):103-110.
5、Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW#. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.. Annals of Oncology,2010;21(5):961-967
6、Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW#. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncology Reports,2010;23(5):1213-20.
7、Yuan Y, Chen XS, Liu SY, Shen KW#. Accuracy of MRI in Prediction of Pathological Complete Remission in Breast Cancer after Preoperative Therapy: A Meta-analysis. AJR,2010;195(1):260-8.
8、Ma CD, Niu XQ, Luo JM, Shao ZM, Shen KW#. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells. Cancer Sci,2010;101(10):2220-6
9、沈坤炜,李宏为. 乳腺癌研究的热点与方向. 外科理论与实践,2010;5:457-459.
10、黄欧,陈灿铭, 吴佳毅, 胡震, 候意枫, 张家新, 柳光宇, 狄根红, 陆劲松, 吴炅, 邵志敏, 沈镇宙, 沈坤炜#. 局部晚期乳腺癌新辅助化疗预后因素分析. 中华外科杂志,2009;47(7):511-5
11、吴佳毅, 沈坤炜#. 预测乳腺癌治疗中蒽环类药物疗效的分子生物学标志物. 肿瘤,2009;29(3):289-294
12、聂秀青,沈坤炜#. 乳腺可疑病灶空芯针穿刺活检后的处理原则. 中国实用外科杂志,2009;29(3):259-260
13、Huang O, Chen C, Wu J, Chen S, Chen X, Liu G, Hu Z, Lu J, Wu J, Shao Z, Shen Z, Shen K#. Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months. BMC Cancer,2009;9: 375
14、Huang O,Wang LP,Shen KW#,Lin H,Hu Z,Liu GY,Wu J,Lu JS,Shao ZM,Han QX,Shen ZZ.. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat,2008;107(3):379-387
15、陈小松, 马传栋, 陈灿铭, 杨文涛, 陆洪芬, 周晓燕, 柳光宇, 狄根红, 吴炅, 陆劲松, 韩企夏, 邵志敏, 沈镇宙, 沈坤炜#. 乳腺癌分子分型与预后关系的研究. 中华外科杂志,2008;46(18):1400-1403
16、陈小松, 陈舒婕, 沈坤炜#. 乳腺癌的分子分型. 中华肿瘤杂志,2008;30(9):5-7
17、Ma CD, Chen CM, Chen XS, Liu GY, Di GH, Wu J, Lu JS, Yang WT, Chen JY, Shao ZM, Shen ZZ, Shen KW#. Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer. Anticancer Res,2008;28(5B):3093-7
|
